Filing Details

Accession Number:
0001104659-13-044256
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-23 14:28:26
Reporting Period:
2013-05-13
Filing Date:
2013-05-23
Accepted Time:
2013-05-23 14:28:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1526119 Verastem Inc. VSTM Pharmaceutical Preparations (2834) 273269467
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291961 H Christoph Westphal C/O Verastem, Inc.,
215 First Street, Suite 440
Cambridge MA 02142
Chief Executive Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-05-13 9 $9.70 703,698 No 4 L Direct
Common Stock Acquisiton 2013-05-13 200 $9.77 703,898 No 4 L Direct
Common Stock Acquisiton 2013-05-13 400 $9.78 704,298 No 4 L Direct
Common Stock Acquisiton 2013-05-13 100 $9.79 704,398 No 4 L Direct
Common Stock Acquisiton 2013-05-13 91 $9.87 704,489 No 4 L Direct
Common Stock Acquisiton 2013-05-21 800 $9.24 705,289 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 L Direct
No 4 L Direct
No 4 L Direct
No 4 L Direct
No 4 L Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,869,841 Indirect By Longwood Fund, L.P.
Common Stock 125,714 Indirect By the Fountain Irrevocable Trust of 2010
Footnotes
  1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2012.
  2. Represents a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $9.23 to $9.27, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2 to this Form 4.
  3. Longwood Fund GP, LLC is the sole General Partner of Longwood Fund, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of the Longwood Shares in this report shall not be deemed an admission of beneficial ownership of the Longwood Shares for purposes of Section 16 or for any other purpose.